GI Innovation Partnership: Advancing Breakthrough Therapies
TCT Sağlık Teknolojileri is proud to collaborate with GI Innovation, a cutting-edge biotechnology company specializing in immuno-oncology and allergy treatments. This partnership aligns with TCT’s mission to bring transformative therapies to Turkey, ensuring access to groundbreaking solutions for cancer and chronic diseases. Below is an overview of GI Innovation’s robust pipeline, powered by its proprietary GI-SMART™ platform.
GI-101: Revolutionizing Immuno-Oncology Therapy
GI-101 is a next-generation immuno-oncology bispecific fusion protein designed to enhance immune activation in the tumor microenvironment. By combining an IL-2 domain that stimulates cytotoxic T and NK cells with a CD80 domain that blocks immune-suppressive mechanisms, GI-101 redefines cancer treatment.
-
-
- Clinical Status: Phase 1/2 trials.
-
- Applications: Being tested in combination with Imfinzi® (durvalumab) and chemotherapy for solid tumors such as small cell lung cancer, gastric cancer, and triple-negative breast cancer.
- Impact: This therapy aims to overcome resistance to traditional treatments, offering new hope for patients with advanced cancers.
-
GI-102: Enhancing Immune Activation Against Tumors
GI-102 is another powerful immuno-oncology candidate designed to amplify the immune system’s ability to fight cancer.
-
-
- Clinical Status: Phase 1/2a trials.
-
- Features: Demonstrates strong immune activation with minimal toxicity.
- Applications: Targets a wide range of cancers and works synergistically with other treatments, such as chemotherapy, to expand its therapeutic reach.
-
GI-301: Targeting IgE-Mediated Allergic Diseases
GI-301 is an innovative therapy designed to neutralize IgE, a key driver of allergic reactions.
-
-
- Clinical Status: Phase 1b trials.
-
- Applications: Addresses conditions such as atopic dermatitis and asthma.
- Global Reach: Out-licensed to Yuhan Corp. in Korea and Maruho in Japan, showcasing strong international interest in its potential to redefine allergy treatment.
-
GI-30N: Tackling Allergic and Fibrotic Diseases
GI-30N focuses on treating allergic and fibrotic diseases by addressing chronic inflammation and tissue scarring.
-
-
- Clinical Status: Early development stage.
- Potential: Represents a critical area of research for addressing conditions that currently lack effective treatment options.
-
GI-20N: Innovative Solutions for Metabolic Diseases
GI-20N targets metabolic diseases, such as non-alcoholic steatohepatitis (NASH), leveraging the GI-SMART™ platform to tackle these global health challenges.
-
-
- Clinical Status: Early development stage.
- Focus: Aims to provide advanced therapeutic options for conditions affecting millions worldwide.
-
Transforming Healthcare with Strategic Partnerships
Through its partnership with GI Innovation, TCT is facilitating the introduction of these groundbreaking therapies into Turkey’s healthcare system. By leveraging GI Innovation’s advanced platforms and pipeline, TCT is accelerating the availability of transformative treatments for patients in Turkey. This collaboration strengthens TCT’s position as a leader in delivering next-generation therapies, bridging the gap between global innovation and local healthcare needs.
Together, TCT and GI Innovation are shaping the future of healthcare, bringing hope and improved outcomes to patients across Turkey and beyond.